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ThioureaHuman polyomaviruses are generally latent but can be reactivated in patients whose immune systems
are suppressed. Unfortunately, current therapeutics for diseases associated with polyomaviruses are
non-specific, have undefined mechanisms of action, or exacerbate the disease. We previously reported
on a class of dihydropyrimidinones that specifically target a polyomavirus-encoded protein, T antigen,
and/or inhibit a cellular chaperone, Hsp70, that is required for virus replication. To improve the antiviral
activity of the existing class of compounds, we performed Biginelli and modified multi-component reac-
tions to obtain new 3,4-dihydropyrimidin-2(1H)-ones and -thiones for biological evaluation. We also
compared how substituents at the N-1 versus N-3 position in the pyrimidine affect activity. We discov-
ered that AMT580-043, a N-3 alkylated dihydropyrimidin-2(1H)-thione, inhibits the replication of a dis-
ease-causing polyomavirus in cell culture more potently than an existing drug, cidofovir.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Polyomaviruses are double stranded DNA viruses that are ende-
mic in the human population but are usually not disease-causing.
However, in individuals who are immune-compromised, select
members of this virus family can be reactivated and cause serious
ailments.1,2 For example, BK virus reactivation in renal transplant
patients undergoing immunosuppressive therapies leads to BK
virus associated nephropathy (BKVAN), which is observed in 5–
10% of all kidney transplant recipients. More than half of these
individuals will ultimately lose the donated organ. BK virus reacti-
vation is also evident in cancer patients who undergo bone marrow
transplants and are given immunosuppressants, leading to hemor-
rhagic cystitis. Similarly, 5–10% of HIV-infected individuals ulti-
mately succumb to progressive multifocal leukoencephalopathy
(PML), which arises from JC virus reactivation. Due to recent
improvements in virus identification and sequencing techniques,
the number of known polyomaviruses has increased, such thatthere are now 12 human polyomavirus types. Several of these
new polyomavirus family members have also been linked to dis-
ease.3 Unfortunately, existing therapeutics to treat polyomavirus
infections are non-specific and/or exhibit unwanted side-effects.4
Cidofovir (CDV), an FDA approved treatment for cytomegalovirus
(CMV) retinitis in AIDS patients, is an acyclic dCMP analog that
inhibits DNA polymerase and is commonly used off-label to treat
polyomavirus infections (Fig. 1).4 Brincidofovir (BCV, CMX001) is
a prodrug of CDV and shares its mechanism of action.5 A cell based
high-throughput screen for simian virus 40 (SV40) and poly-
omavirus (BK and JC) inhibitors also detected activity with ellagic
acid and spiperone.6
We previously reported on the synthesis, screening, and
preliminary structure–activity relationship (SAR) studies of
multi-component reaction-derived dihydropyrimidinones that
inhibit the growth of polyomaviruses, in particular MAL2-11B,
BQU015242, LR340-006, ML282-56, and ML282-86 (SMAL)
(Fig. 1); we also identified hexachlorophene and bithionol as poly-
omavirus inhibitors.7–11 The most specific dihydropyrimidinone
compounds were identified based on their ability to inhibit the
ATPase activity of T antigen, which is a polyomavirus-encoded
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Figure 1. Inhibitors of BK polyomavirus replication and propagation.
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replication of the polyomavirus genome.12 Some of our poly-
omavirus inhibitors also compromised the ability of T antigen,
which contains a region with homology to Hsp40 chaperones, to
activate the ATPase activity of the Hsp70 molecular chaperone.
Hsp70 is required for T antigen-catalyzed polyomavirus replica-
tion.13,14 Our most potent compound, SMAL,7 inhibited T antigen
ATPase activity with an IC50 of 5 lM. However, SMAL was as effec-
tive in cell-based viral replication assays as compounds that were
less potent in the in vitro ATPase assay. Therefore, in order to iden-
tify improved inhibitors of polyomavirus replication, we now syn-
thesized and characterized a class of SMAL variants that bear a
thiourea group in place of the urea moiety in the dihydropyrimidi-
nones (Fig. 2). This modification allowed us to investigate the influ-
ence of electronic and physicochemical inhibitor properties on
antiviral activity, such as: (1) the greater electron-density and
polarizability of the thiocarbonyl compared to the carbonyl group;
(2) the modification of H-bond donor (HBD) and H-bond acceptor
(HBA) properties in the thiourea versus urea, and (3) the increased
acidity of the thiourea NH group versus the amide NH.15,16 In addi-
tion, we switched key moieties at the N-1 and N-3 positions in the
heterocycle to determine whether altered placement of active side
chains affects T antigen and Hsp70 inhibition.N
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Figure 2. Structures of heterocyclic cores probed in this work and compound MAL3-10
LR340-006, ML282-56, and ML282-86 (SMAL). See Supplemental materials for an overvie
structures for all assayed analogs, as well as their sequential compound numbers fromThe synthesis of N-1 substituted 3,4-dihydropyrimidine-2(1H)-
thiones was achieved through a series of Biginelli reactions
(Scheme 1).17–19 Thioureas 2a–c were obtained in 61–78% yield
by condensation of amines 1 with thiocarbonyldiimidazole (TCDI)
in the presence of triethylamine, followed by aminolysis with
aqueous ammonia. According to a procedure described by Tol-
machev and co-workers,20 2c was sonicated in the presence of
[1,10-biphenyl]-4-carbaldehyde, benzyl 3-oxobutanoate and TMSCl
for 1 h and subsequently stirred at rt for several days, followed by
saponification with 1 N NaOH to yield the desired Biginelli acid 3e
(AMT551-090). In an analogous fashion, thioureas 2a and 2b were
converted to the heterocycle-linked nitriles which were further
modified with trimethylsilylazide and TBAF to give the corre-
sponding tetrazoles 3a–d.
The synthesis of the regioisomeric N-3 alkylated analogs of
dihydropyrimidinethiones 3 used the Atwal modification of the
Biginelli reaction (Scheme 2). Enones 4 were condensed with 2-
(4-methoxybenzyl)isothiouronium chloride (5) in the presence of
sodium acetate in DMF to give the desired isothioureas 6 in 64–
81% yield. Regioselective N-3 alkylation21 with bromonitrile and
bromoester electrophiles gave the dihydropyrimidines 7a–c in
54–62% yield. Nitriles 7a and 7b were converted to tetrazoles 8a
and 8b, respectively, whereby tetrazole formation with TMS-azideN
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proceed or follow the S-debenzylation with ethanethiol and
trifluoroacetic acid (TFA). The 2-(trimethylsilyl)ethyl (TMSE) ester
7c was desialylated with tetrabutylammonium fluoride (TBAF)
before cleavage of the isothiourea with ethanethiol and TFA to give
acid 8c.
Finally, in order to compare the effect of N-3 versus N-1 substi-
tution on the dihydropyrimidinone in the carbonyl series, we also
prepared tetrazole 12 (Scheme 3). The enone 4a was reacted with
methyl isourea hydrochloride 9 in the presence of NaHCO3 in DMF
to give methoxy pyrimidine 10, which was selectively alkylated
with 4-(bromomethyl)benzonitrile to give 11 in 38% overall yield
from 9. After hydrolysis of the isourea moiety, tetrazole formation
with TMS-azide provided dihydropyrimidinone 12, which differed
from dihydropyrimidinethione 8a solely by the presence of acarbonyl function in place of the thiocarbonyl group at C-2 of the
6-membered heterocycle.
Previously, we had found that SMAL and certain SMAL analogs
inhibited both the ATPase activity of T antigen and the ability of
T antigen’s homologous Hsp40 domain to stimulate Hsp70 ATPase
activity;7 therefore, we assessed all new compounds and several
control molecules for their ability to affect the ATPase activity of
human Hsp70 in the presence or absence of a human Hsp40 homo-
log, Hdj2 (see Supplemental materials). Consistent with previous
data,7,10 SMAL and a SMAL analog, BQU015242, modestly inhibited
the endogenous Hsp70 ATPase activity but had a more pronounced
effect on Hsp40-activated Hsp70 activity (4.3- and 1.3-fold, respec-
tively; Table 1). Most striking was AMT580-043, which inhibited
the co-chaperone stimulated activity by 5.3-fold. Because
AMT551-078 was somewhat less active (4.5-fold inhibition), we
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Table 1
Fold change differences in ATPase activity of Hsp70 in the presence or absence of an
Hsp40, Hdj2, and the indicated compounds (at a final concentration of 100 lM). The
activity of purified T antigen was examined in the presence of a final concentration of
10 lM compounda
Compd Hsp70 Hsp70+Hdj2 T antigen
SMAL 1.2 4.3 4.3
BQU015242 1.2 1.3 1.4
AMT551-093 (3b) NC 3.7 7.7
ML282-56 NC 5.0 2.0
AMT551-078 (3a) 1.4 4.5 5.5
AMT551-058 (8b) 1.3 4.8 7.5
AMT628-003 (12) 1.2 5.0 2.3
AMT580-043 (8a) 1.7 5.3 4.5
LR340-006 1.4 3.0 2.1
AMT580-033 (3d) NC 2.5 4.7
AMT580-027 (3c) NC 1.7 2.1
MAL2-11B NC +1.5 1.5
AMT551-090 (3e) NC NC 1.5
AMT551-071 (8c) NC NC 1.6
Data were normalized to activities in reactions lacking compound but containing an
equivalent amount of DMSO. Reactions contained a 1:0.5 molar ratio of Hsp70/
Hsp40. Data represent the means of three independent experiments.
a NC, no statistically significant change in activity.
5090 A. Manos-Turvey et al. / Bioorg. Med. Chem. Lett. 26 (2016) 5087–5091concluded that substitution at the N-3 position versus the N-1
position appears to augment the inhibitory activity. Furthermore,
the AMT580-043 dihydropyrimidinethione was slightly more
active than the AMT628-003 dihydropyrimidinone (5.3-fold versus
5.0-fold inhibition). In each of these compounds, replacing the flex-
ible linker that ties the tetrazole to the dihydropyrimidine with the
more rigid phenyl group in the side chain increased activity.
Derivatives containing a carboxylic acid in place of the tetrazole
(e.g., MAL2-11B or AMT551-090) either lacked inhibitory activity
or modesty stimulated Hsp40-dependent activation of Hsp70. We
also examined the ability of each compound to inhibit the ATPase
activity of purified T antigen, as previously published.7 As shown in
Table 1, several compounds exhibited robust inhibition of activity.
First, consistent with the reported EC50 for SMAL (5 lM),7 this
compound significantly reduced the ATPase activity of T antigenTable 2
GI50 (lM) values for the indicated compounds against RMS13 and MCF7 cellsa
Compd RMS13 MCF7
MAL3-101 13 ± 9 6.0 ± 1
SMAL 73 ± 4 140 ± 6
AMT551-093 68 ± 1 160 ± 18
ML282-56 96 ± 5 160 ± 9
AMT551-078 87 ± 5 140 ± 7
AMT551-058 62 ± 7 ND
AMT580-043 72 ± 6 110 ± 4
ND, not determined.
a Fifty-percent growth inhibition of the indicated cell lines in the presence of the comp
means of 2 independent experiments each run in triplicate, ±SD.when applied at a final concentration of 10 lM. Second, an analysis
of the remaining compounds extends the SAR obtained in our pre-
vious work.7 We find that the thiourea moiety in combination with
a tetrazole in the side chain is necessary but not sufficient for inhi-
bition of T antigen activity. Although not without exception (e.g.,
AMT580-027), the compounds that contain both of these motifs
are the most active inhibitors. One possibility is that the active
compound complex with zinc or interfere with the zinc-finger
domain in T antigen, which might disrupt the structure of this hex-
americ ATPase. This hypothesis will be examined in future studies.
The ultimate goal of our program is to identify more potent and
efficacious compounds that inhibit the replication of poly-
omaviruses. Therefore, we next tested whether representative
compounds inhibit the growth of human cells in culture. Many
cancer cell lines rely on Hsp70 for proliferation,22 and to begin to
determine whether members of this new compound series were
cytotoxic, we measured the 50% growth inhibition (GI50) values
of select compounds when incubated with a rhabdomyosarcoma
cell line (RMS13) as well as with a breast cancer cell line, MCF7
(see Supplemental material). MAL3-101, the parent lead structure
for SMAL and all of the compounds reported herein, was used as
a positive control as this dihydropyrimidinone inhibits the growth
of cancer cells both in vitro and in vivo.8,23,24 As anticipated, MAL3-
101 inhibited the growth of the two cancer lines with a GI50 of
6.0–13 lM (Table 2). In contrast, all of the newly prepared
compounds were significantly less toxic, with GI50 values of
62–124 lM.
Because the novel dihydropyrimidines were less toxic than
MAL3-101, and because some of the compounds were significantly
more potent inhibitors than MAL3-101 in ATPase assays, we next
measured the replication of BK virus and JC virus, which, respec-
tively, lead to BKVAN and PML in immunocompromised patients
(see above). Specifically, we examined the activity of AMT580-
043 in polyomavirus infected cells because this was the most
potent compound in the Hsp40-Hsp70 ATPase assay (Table 1).
We then compared the activity of AMT580-043 with
BQU015242,10 SMAL,7 and cidofovir. As shown in Table 3, each of
these four compounds inhibited the replication of BKV in humanCompd RMS13 MCF7
LR340-006 100 ± 7 72 ± 1
AMT580-033 100 ± 8 ND
AMT580-027 110 ± 0.0 ND
MAL2-11B 120 ± 6 ND
AMT551-090 100 ± 3 ND
AMT551-071 110 ± 3 ND
ounds was calculated as described in the Supplemental materials. Data represent the
Table 3
Antiviral activity of select pyrimidines against BK virus in human foreskin fibroblasts
Compd EC50a (lM) CC50a (lM)
BQU015242 3.9 ± 4.0b >67 ± 46b
SMAL 1.7 ± 0.76c 20 ± 17.8c
AMT580-043 1.8 ± 0.86c 17 ± 1.7c
Cidofovir 1.1 ± 1.2c >100 ± 0c
a EC50: effective concentration at which 50% activity is evident; CC50: cytotoxic
concentration to cause death in 50% of viable cells.
b Values shown are from two independent experiments.
c Values shown represent the average EC50 value and CC50 value from three
independent experiments ± SD.
Table 4
Antiviral activity of select pyrimidines against JC virus in COS7 cells
Compd EC50a (lM) CC50a (lM)
BQU015242 3.5 ± 2.6 24 ± 3.1
SMAL 4.2 ± 2.5 21 ± 1.0
AMT580-043 0.75 ± 0.6 18 ± 0.17
Cidofovir 2.0 ± 1.6 49 ± 0.1
a Values shown represent the average EC50 value and CC50 value from two
independent experiments.
A. Manos-Turvey et al. / Bioorg. Med. Chem. Lett. 26 (2016) 5087–5091 5091foreskin fibroblasts with similar potency, and EC50 values ranged
from 1.1 lM (cidofovir) to 3.9 lM (BQU015242). However, cido-
fovir was significantly less toxic than the dihydropyrimidines. In
contrast, when the replication of JCV was assessed in green mon-
key kidney cells (COS-7), AMT580-043 was by far the most potent
compound, with an EC50 of 0.75 lM versus an EC50 of 2.0 lM for
cidofovir (Table 4). It is also noteworthy that AMT580-043 is one
of the most potent inhibitors of T antigen ATPase activity examined
in this study (Table 1). Moreover, the specificity indices (CC50/EC50)
for AMT580-043 and cidofovir were essentially identical (23 and
24, respectively). These results indicate that AMT580-043 should
be further optimized to offset the catastrophic consequences of
PML, a disease that has a 3-month mortality rate of 20–50%.24
While some of the physicochemical features of AMT580-043
(MW 572.7, logP 6.4) are still in need of improvement, other
parameters (logD 4.8, HBA 4, HBD 2, number of rotatable bonds
<10, passes Veber filter25) are attractive, making this compound a
suitable lead structure for further medicinal chemistry
optimization.
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